
Sinovac Biotech, Ltd.: updates and filings
Price
$6.47
November 18, 2026Market cap $465M
What Ploutos Investor adds for Sinovac Biotech
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- A figure that did not match the numbers it is built from has been left out.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Aug 17, 2026Current report (foreign company)Form6-K
- Jul 15, 2026Current report (foreign company)Form6-K
- Jun 15, 2026Current report (foreign company)Form6-K
- Jun 5, 2026Current report (foreign company)Form6-K
- Jun 5, 2026Annual report (foreign company)for the period to Dec 31, 2025Form20-F
- May 29, 2026Current report (foreign company)Form6-K
- May 21, 2026Current report (foreign company)Form6-K
- May 8, 2026Current report (foreign company)Form6-K
- May 7, 2026Current report (foreign company)Form6-K
- Apr 30, 2026Notice that the annual report will be filed lateFormNT 20-F
- Apr 30, 2026Annual report (foreign company)for the period to Dec 31, 2024Form20-F
- Jan 22, 2026Current report (foreign company)Form6-K
- Jan 5, 2026Current report (foreign company)Form6-K
- Dec 17, 2025Current report (foreign company)Form6-K
- Dec 17, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 20, 2025Current report (foreign company)Form6-K
- Nov 5, 2025Current report (foreign company)Form6-K
- Sep 12, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 21, 2025Current report (foreign company)Form6-K
- Jul 15, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jul 14, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jul 14, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jul 11, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jul 11, 2025Current report (foreign company)Form6-K
- Jul 10, 2025Current report (foreign company)Form6-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Aug 17, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 15, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 15, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 5, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 5, 2026 | 20-F | Annual report (foreign company)for the period to Dec 31, 2025 | Document |
| May 29, 2026 | 6-K | Current report (foreign company) | Document |
| May 21, 2026 | 6-K | Current report (foreign company) | Document |
| May 8, 2026 | 6-K | Current report (foreign company) | Document |
| May 7, 2026 | 6-K | Current report (foreign company) | Document |
| Apr 30, 2026 | NT 20-F | Notice that the annual report will be filed late | Document |
| Apr 30, 2026 | 20-F | Annual report (foreign company)for the period to Dec 31, 2024 | Document |
| Jan 22, 2026 | 6-K | Current report (foreign company) | Document |
| Jan 5, 2026 | 6-K | Current report (foreign company) | Document |
| Dec 17, 2025 | 6-K | Current report (foreign company) | Document |
| Dec 17, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 20, 2025 | 6-K | Current report (foreign company) | Document |
| Nov 5, 2025 | 6-K | Current report (foreign company) | Document |
| Sep 12, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 21, 2025 | 6-K | Current report (foreign company) | Document |
| Jul 15, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jul 14, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jul 14, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jul 11, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jul 11, 2025 | 6-K | Current report (foreign company) | Document |
| Jul 10, 2025 | 6-K | Current report (foreign company) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 20, 2000.
The full analysis
What do Sinovac Biotech's filings show?
The filings are where every one of Sinovac Biotech's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.